首页> 外文期刊>Current Opinion in Virology >HIV-1 reverse transcriptase and antiviral drug resistance. Part 1
【24h】

HIV-1 reverse transcriptase and antiviral drug resistance. Part 1

机译:HIV-1逆转录酶和抗病毒药物耐药性。第1部分

获取原文
获取原文并翻译 | 示例
           

摘要

HIV-1 reverse transcriptase (RT) contributes to the development of resistance to all anti-AIDS drugs by introducing mutations into the viral genome. At the molecular level, mutations in RT result in resistance to RT inhibitors. Eight nucleosideucleotide analogs (NRTIs) and five non-nucleoside inhibitors (NNRTIs) are approved HIV-1 drugs. Structures of RT have been determined in complexes with substrates and/or inhibitors, and the structures have illuminated different conformational and functional states of the enzyme. Understanding the molecular mechanisms of resistance to NRTIs and NNRTIs, and their complex relationships, may help in designing new drugs that are periodically required to overcome existing as well as emerging trends of drug resistance.
机译:HIV-1逆转录酶(RT)通过将突变引入病毒基因组来促进对所有抗艾滋病药物的耐药性。在分子水平上,RT的突变会导致对RT抑制剂的抵抗。八种核苷/核苷酸类似物(NRTIs)和五种非核苷抑制剂(NNRTIs)被批准为HIV-1药物。已经确定了RT的结构与底物和/或抑制剂的复合物,并且该结构已经阐明了酶的不同构象和功能状态。了解对NRTIs和NNRTIs耐药的分子机制及其复杂的关系,可能有助于设计新药,这些新药需要定期克服现有和新兴的耐药性趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号